BioSpace News Archive

Takeda’s vedolizumab met its primary endpoint in the Phase III GRAPHITE study, significantly improving event-free survival in patients with acute graft-versus-host disease.

Hemab Therapeutics announced the closing of an oversubscribed Series B round to bring new treatment options for lesser-known bleeding disorders.

The FDA granted accelerated approval Friday to Travere Therapeutics’ sparsentan, now to be marketed as Filspari, to reduce the burden of proteinuria in adults with primary IgA nephropathy.

On Friday, the FDA approved Apellis Pharmaceuticals’ Syfovre (pegcetacoplan) as the first treatment for geographic atrophy (GA), a leading cause of blindness.

Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data from the Veterans Affairs BRAVO study at the ASCO Genitourinary Cancers Symposium which was held February 16-18, 2023 in San Francisco, USA.

Regenative Labs (Regenative), a leading HCT/P manufacturer, announces updates to its 2022 MDPI retrospective study on tissue defects in and around the knee.

Immunovia AB, reg. no. 556730-4299, hereby gives notice that an Extraordinary General Meeting will take place on Thursday 16th March 2023 at 10.00 at The Spark, Scheeletorget 1, Medicon Village, in Lund.

Medivir AB announced that the initial dose escalation part of the company’s 1b/2a study with the candidate drug fostroxacitabine bralpamide in hepatocellular carcinoma, in combination with Lenvima®, was successfully completed.

Azafaros B.V. today announced its progress in ongoing interactions with Health Authorities regarding its lead asset, AZ-3102.

Henry Schein, Inc. announced its presence at the 2023 Chicago Dental Society Midwinter meeting, featuring a comprehensive display of the Company’s expansive portfolio of products and solutions, designed to help oral health professionals enhance every aspect of their practice efficiency and the patient experience.